Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | Global President TAVR & Surg | August 18, 2025 | August 18, 2025 |
| PROCEPT BioRobotics CorpPRCT · Entity 4831 | Director · President, CEO | August 07, 2026 | August 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date August 18, 2025 · Filed August 18, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 206,900.3913 |
Ending reported balance
After 2025-08-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-08-18 · Exercise / conversion · Acquired 8,950 · Balance 215,850.3913 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. Row 2 · 2025-08-18 · Sale · Disposed 8,950 · Balance 206,900.3913 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. F2: This transaction was executed in multiple trades at prices ranging from $77.68 to $78.43. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| Employee Stock Option (Right to Acquire)SEC Table II · derivative / convertible security · Conversion / exercise price $59.26 · Expires 2026-05-07 | Direct | 35,800 |
Reported balance
After 2025-08-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-08-18 · Exercise / conversion · Disposed 8,950 · Balance 35,800 |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 148.1703 |
Reported balance
Holding disclosure · report date 2025-08-18 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 148.1703 |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $77.68 to $78.43. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
PROCEPT BioRobotics Corp
Report date August 07, 2026 · Filed August 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectThe Larry Wood Trust | 23,900 |
Reported balance
After 2026-08-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-07 · Purchase · Acquired 23,900 · Balance 23,900 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.67 to $21.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. |
| Common StockSEC Table I · non-derivative | Direct | 314,203 |
Reported balance
Holding disclosure · report date 2026-08-07 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 314,203 F2: Includes 825 shares acquired on May 14, 2026, under the Issuer's 2021 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.67 to $21.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2: Includes 825 shares acquired on May 14, 2026, under the Issuer's 2021 Employee Stock Purchase Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2020 Filed Apr 1, 2020 22:30 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,566 | $65.28 | $232,788.48 |
DisclosureSEC source: 0001225208-20-005798 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,101.9047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| March 02, 2020 Filed Mar 2, 2020 23:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,566 | $0.00 Strike: $65.28 | $0.00 |
DisclosureSEC source: 0001225208-20-003950 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,102 Underlying: Common Stock · 3,566 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| March 02, 2020 Filed Mar 2, 2020 23:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,566 | $207.00 | $738,162.00 |
DisclosureSEC source: 0001225208-20-003950 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,428.6071 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| March 02, 2020 Filed Mar 2, 2020 23:54 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,566 | $65.28 | $232,788.48 |
DisclosureSEC source: 0001225208-20-003950 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,994.6071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 01:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,566 | $0.00 Strike: $65.28 | $0.00 |
DisclosureSEC source: 0001225208-20-001531 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,668 Underlying: Common Stock · 3,566 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 01:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,566 | $219.50 | $782,737.00 |
DisclosureSEC source: 0001225208-20-001531 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,428.6071 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| February 03, 2020 Filed Feb 4, 2020 01:57 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,566 | $65.28 | $232,788.48 |
DisclosureSEC source: 0001225208-20-001531 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,994.6071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 3,566 | $0.00 Strike: $65.28 | $0.00 |
DisclosureSEC source: 0001225208-20-000064 · doc4.xml · derivative · entry 6 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,234 Underlying: Common Stock · 3,566 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 5,002 | $0.00 Strike: $34.05 | $0.00 |
DisclosureSEC source: 0001225208-20-000064 · doc4.xml · derivative · entry 5 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,002 shares Expires 2021-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 8,568 | $229.98 | $1,970,468.64 |
DisclosureSEC source: 0001225208-20-000064 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,428.6071 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 3,566 | $65.28 | $232,788.48 |
DisclosureSEC source: 0001225208-20-000064 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,996.6071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 00:25 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 5,002 | $34.05 | $170,318.10 |
DisclosureSEC source: 0001225208-20-000064 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,430.6071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 12, 2019. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 17:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,724 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-015491 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,724 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 17:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,724 | $238.56 | $1,604,077.44 |
DisclosureSEC source: 0001225208-19-015491 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,428.6071 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| December 09, 2019 Filed Dec 10, 2019 17:29 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,724 | $41.94 | $282,004.56 |
DisclosureSEC source: 0001225208-19-015491 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,152.6071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| November 01, 2019 Filed Nov 2, 2019 00:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-014027 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,724 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| November 01, 2019 Filed Nov 2, 2019 00:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,716 | $239.75 | $1,610,161.00 |
DisclosureSEC source: 0001225208-19-014027 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,428.6071 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| November 01, 2019 Filed Nov 2, 2019 00:37 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-014027 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,144.6071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| October 01, 2019 Filed Oct 1, 2019 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-012949 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,440 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| October 01, 2019 Filed Oct 1, 2019 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,716 | $218.24 | $1,465,699.84 |
DisclosureSEC source: 0001225208-19-012949 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,428.6071 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| October 01, 2019 Filed Oct 1, 2019 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-012949 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,144.6071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| September 03, 2019 Filed Sep 3, 2019 23:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-012059 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,156 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| September 03, 2019 Filed Sep 3, 2019 23:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,716 | $219.91 | $1,476,915.56 |
DisclosureSEC source: 0001225208-19-012059 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,428.6071 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| September 03, 2019 Filed Sep 3, 2019 23:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-012059 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,144.6071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 22:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-010796 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,872 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 22:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,716 | $213.31 | $1,432,589.96 |
DisclosureSEC source: 0001225208-19-010796 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,428.6071 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| August 01, 2019 Filed Aug 1, 2019 22:56 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-010796 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,144.6071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| July 01, 2019 Filed Jul 1, 2019 22:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-009690 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,588 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| July 01, 2019 Filed Jul 1, 2019 22:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,716 | $186.95 | $1,255,532.69 |
DisclosureSEC source: 0001225208-19-009690 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,428.6071 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. F2 · price: This transaction was executed in multiple trades at prices ranging from $186.68 to $187.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2019 Filed Jul 1, 2019 22:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-009690 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,144.6071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| June 03, 2019 Filed Jun 3, 2019 20:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-008725 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,304 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| June 03, 2019 Filed Jun 3, 2019 20:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,716 | $169.75 | $1,140,041.00 |
DisclosureSEC source: 0001225208-19-008725 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,385.9386 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| June 03, 2019 Filed Jun 3, 2019 20:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-008725 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,101.9386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| May 14, 2019 Filed May 15, 2019 00:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,066 | $178.17 | $189,929.22 |
DisclosureSEC source: 0001225208-19-008003 · doc4.xml · nonDerivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,385.9386 Read SEC document |
| May 12, 2019 Filed May 15, 2019 00:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionPerformance Rights · Derivative | 2,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-008003 · doc4.xml · derivative · entry 6 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,689 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.exercise_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.expiration_date: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · derivative.underlying_shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 15, 2019 00:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 1,334 | $181.10 | $241,587.40 |
DisclosureSEC source: 0001225208-19-008003 · doc4.xml · nonDerivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,451.9386 F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 12, 2019 Filed May 15, 2019 00:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 707 | $181.10 | $128,037.70 |
DisclosureSEC source: 0001225208-19-008003 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,785.9386 Read SEC document |
| May 12, 2019 Filed May 15, 2019 00:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 2,689 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-008003 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,492.9386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. F1 · price: On May 12, 2016, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 7, 2019, the Compensation Committee of the Board of Directors determined that 75.77% of the target shares would vest as of May 12, 2019, and the actual number of shares vested are reflected on this Form and the balance of the award terminated. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantPerformance Rights · Derivative | 2,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000036 · primary_doc.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,525 Underlying: Common Stock · 2,525 shares Expires 2026-05-07 F4 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.exercise_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. F4 · derivative.underlying_shares: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 8, 2019 and scheduled to vest on May 8, 2022. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 17,900 | $0.00 Strike: $177.77 | $0.00 |
DisclosureSEC source: 0001223203-19-000036 · primary_doc.xml · derivative · entry 3 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,900 Underlying: Common Stock · 17,900 shares Expires 2026-05-07 F3 · derivative.exercise_date: These options were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2019 Filed May 10, 2019 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-19-000036 · primary_doc.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,803.9386 F1 · shares: These restricted stock units were granted on May 8, 2019 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become 50% vested three years after the grant date and 50% vested four years after the grant date. Read SEC document |
| May 01, 2019 Filed May 1, 2019 22:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-007509 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,020 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| May 01, 2019 Filed May 1, 2019 22:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,716 | $176.34 | $1,184,299.44 |
DisclosureSEC source: 0001225208-19-007509 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,778.9386 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| May 01, 2019 Filed May 1, 2019 22:58 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-007509 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,494.9386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| April 01, 2019 Filed Apr 1, 2019 21:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-005950 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,736 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| April 01, 2019 Filed Apr 1, 2019 21:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,716 | $192.34 | $1,291,744.69 |
DisclosureSEC source: 0001225208-19-005950 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,778.9386 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| April 01, 2019 Filed Apr 1, 2019 21:23 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-005950 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,494.9386 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| March 01, 2019 Filed Mar 2, 2019 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 6,716 | $0.00 Strike: $41.94 | $0.00 |
DisclosureSEC source: 0001225208-19-004205 · doc4.xml · derivative · entry 4 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,452 Underlying: Common Stock · 6,716 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| March 01, 2019 Filed Mar 2, 2019 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 6,716 | $170.82 | $1,147,227.12 |
DisclosureSEC source: 0001225208-19-004205 · doc4.xml · nonDerivative · entry 2 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,649.8685 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
| March 01, 2019 Filed Mar 2, 2019 00:02 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 6,716 | $41.94 | $281,669.04 |
DisclosureSEC source: 0001225208-19-004205 · doc4.xml · nonDerivative · entry 1 Wood Larry L · CIK 0001440660 · CVP, TAVR 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,365.8685 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.